PFM
ITCI

Privium Fund Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Privium Fund Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-97,154
Closed -$8.11M – 68
2024
Q4 		$8.11M Sell
97,154
-20,829
-18% -$1.71M 1.84% 13
2024
Q3 		$8.63M Hold
117,983
– – 2.15% 13
2024
Q2 		$8.09M Buy
117,983
+9,100
+8% +$631K 2.06% 13
2024
Q1 		$7.53M Buy
108,883
+14,900
+16% +$1.02M 2.01% 15
2023
Q4 		$6.62M Buy
93,983
+333
+0.4% +$19.2K 1.85% 17
2023
Q3 		$4.88M Buy
93,650
+10,000
+12% +$583K 1.45% 21
2023
Q2 		$5.18M Buy
+83,650
New +$5.21M 1.49% 21

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Privium Fund Management's ITCI Position: Q1 2025 in Review

Privium Fund Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 97,154 shares — an estimated $8.11M sold.

Privium Fund Management first reported a position in ITCI in Q2 2023 and held it in 7 quarters. The position peaked at $8.63M in Q3 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Privium Fund Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Privium Fund Management sold 97,154 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $8.11M.
  • Privium Fund Management first reported a position in Intra-Cellular Therapies Inc. in Q2 2023 and held it in 7 quarters.
  • Privium Fund Management's Intra-Cellular Therapies Inc. position peaked at $8.63M in Q3 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Privium Fund Management's 13F filing for Q1 2025, filed 9 May 2025.